EClinicalMedicine · 2026
Obesity at antiretroviral therapy initiation and long-term risk of cardiovascular disease, cancer, or death in people with HIV in Italy: a prospective cohort study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mussini Cristina, Giacomelli Andrea, Lapadula Giuseppe, Di Biagio Antonio, Gori Andrea, Orofino Giancarlo, Quiros-Roldan Eugenia, Cingolani Antonella, Madeddu Giordano, Mazzotta Valentina, Rossotti Roberto, Lo Caputo Sergio, Marchetti Giulia, Chester Johanna, Monforte Antonella d'Arminio, Guaraldi Giovanni, Cozzi-Lepri Alessandro, Italian Cohort Naive Antiretrovirals (Icona) Foundation study for the Icona Foundation Study Groupt, Italian Cohort Naive Antiretrovirals (Icona) Foundation study for the Icona Foundation Study Group
Аннотация
BACKGROUND: Altered adipose tissue biology plays a key role in the development of cardiovascular disease (CVD) and cancer and contributes to mortality. We assessed the association between obesity in people with HIV (PWH) at antiretroviral therapy (ART) initiation and the risk of clinical events.
METHODS: In this prospective cohort study, we included ART-naïve adults PWH enrolled in the Italian Cohort Naive Antiretrovirals (Icona) Foundation study cohort in Italy across 96 sites between January 1997 and July 2025. Participants were included if they initiated ART, had body mass index (BMI) > 18.5 kg/m2, and were free from AIDS, CVD, and cancer at ART initiation. Participants were classified as having obesity, defined as BMI ≥ 30 kg/m2, or not having obesity, defined as BMI 18.5-29.9 kg/m2, at ART initiation. The primary outcome was the first occurrence of CVD, cancer, or death. We performed a standard survival analysis with time-fixed covariates at baseline with a composite outcome of CVD/cancer/death. We hypothesized that age may be an effect measure modifier: results are presented after stratification by age (young [18-30], middle aged [31-60] and older [>60 years]).
FINDINGS: A total of 11,652 PWH (20.7% females, median age 38 years [Inter Quartile Range (IQR): 31, 46]) were included: 11,005 (94.4%) were people without obesity and 647 (5.6%) people with obesity. A total of 837 events were recorded: 122 CVD, 374 cancers and 341 deaths. By 15 years from ART initiation, the risk of CVD/cancer/death was 19.1% in people with obesity (95% Confidence Interval [CI]: 14.1-24.9%) vs. 12.4% in people without obesity (95% CI:11.3-13.4%, log-rank p = 0.0029). After controlling for confounding, the difference was attenuated (adjusted hazard ratio [aHR] 1.28 [95% CI:0.98-1.67], p = 0.073). Although we did not find evidence for interaction (p-value = 0.758) there was a trend for a larger effect among younger PWH: young (aHR 1.83 [95% CI 0.74, 4.56]), middle aged (aHR 1.49 [95% CI 1.11, 2.00]) and older (aHR 1.20 [95% CI 0.60, 2.41]).
INTERPRETATION: Obesity at ART initiation may be associated with a clinically meaningful increase in the risk of CVD, cancer, and death. We found weak evidence of a possible age-related gradient, with larger effect size in PWH under 60 years of age, which warrants further investigation.
FUNDING: The Italian Cohort Naive Antiretrovirals (Icona) Foundation Study is supported by unrestricted grants from Gilead Sciences, ViiV Healthcare, Merck Sharpe & Dohme.
METHODS: In this prospective cohort study, we included ART-naïve adults PWH enrolled in the Italian Cohort Naive Antiretrovirals (Icona) Foundation study cohort in Italy across 96 sites between January 1997 and July 2025. Participants were included if they initiated ART, had body mass index (BMI) > 18.5 kg/m2, and were free from AIDS, CVD, and cancer at ART initiation. Participants were classified as having obesity, defined as BMI ≥ 30 kg/m2, or not having obesity, defined as BMI 18.5-29.9 kg/m2, at ART initiation. The primary outcome was the first occurrence of CVD, cancer, or death. We performed a standard survival analysis with time-fixed covariates at baseline with a composite outcome of CVD/cancer/death. We hypothesized that age may be an effect measure modifier: results are presented after stratification by age (young [18-30], middle aged [31-60] and older [>60 years]).
FINDINGS: A total of 11,652 PWH (20.7% females, median age 38 years [Inter Quartile Range (IQR): 31, 46]) were included: 11,005 (94.4%) were people without obesity and 647 (5.6%) people with obesity. A total of 837 events were recorded: 122 CVD, 374 cancers and 341 deaths. By 15 years from ART initiation, the risk of CVD/cancer/death was 19.1% in people with obesity (95% Confidence Interval [CI]: 14.1-24.9%) vs. 12.4% in people without obesity (95% CI:11.3-13.4%, log-rank p = 0.0029). After controlling for confounding, the difference was attenuated (adjusted hazard ratio [aHR] 1.28 [95% CI:0.98-1.67], p = 0.073). Although we did not find evidence for interaction (p-value = 0.758) there was a trend for a larger effect among younger PWH: young (aHR 1.83 [95% CI 0.74, 4.56]), middle aged (aHR 1.49 [95% CI 1.11, 2.00]) and older (aHR 1.20 [95% CI 0.60, 2.41]).
INTERPRETATION: Obesity at ART initiation may be associated with a clinically meaningful increase in the risk of CVD, cancer, and death. We found weak evidence of a possible age-related gradient, with larger effect size in PWH under 60 years of age, which warrants further investigation.
FUNDING: The Italian Cohort Naive Antiretrovirals (Icona) Foundation Study is supported by unrestricted grants from Gilead Sciences, ViiV Healthcare, Merck Sharpe & Dohme.